Vemurafenib or dabrafenib are not approved for this indication yet, and are used off label also in the USA, but are marketed for BRAF-mutated melanoma worldwide and the efficacy of vemurafenib plus rituximab seems higher [17] than that of Moxe [11]. The gene discussed is BRAF; the disease is melanoma.